FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129155102> ?p ?o ?g. }

• W2129155102 endingPage "171" @default.
• W2129155102 startingPage "171" @default.
• W2129155102 abstract "Cardiac gene therapy for heart disease is a major translational research area with potential, yet problems with safe and efficient gene transfer into cardiac muscle remain unresolved. Existing methodology to increase vector uptake include modifying the viral vector, non-viral particle encapsulation and or delivery with device systems. These advanced methods have made improvements, however fail to address the key problem of inflammation in the myocardium, which is known to reduce vector uptake and contribute to immunogenic adverse events. Here we propose an alternative method to co-deliver anti-inflammatory drugs in a controlled release polymer with gene product to improve therapeutic effects.A robust, double emulsion production process was developed to encapsulate drugs into nanoparticles. Briefly in this proof of concept study, aspirin and prednisolone anti-inflammatory drugs were encapsulated in various poly-lactic glycolic acid polymer (PLGA) formulations. The resultant particle systems were characterized, co-delivered with GFP plasmid, and evaluated in harvested myocytes in culture for uptake.High quality nanoparticles were harvested from multiple production runs, with an average 64 ± 10 mg yield. Four distinct particle drug system combinations were characterized and evaluated in vitro: PLGA(50:50) Aspirin, PLGA(65:35) Prednisolone, PLGA(65:35) Aspirin and PLGA(50:50) Prednisolone Particles consisted of spherical shape with a narrow size distribution 265 ± 104 nm as found in scanning electron microscopy imaging. Prednisolone particles regardless of PLGA type were found on average ≈ 100 nm smaller than the aspirin types. All four groups demonstrated high zeta potential stability and re-constitution testing prior to in vitro. In vitro results demonstrated co uptake of GFP plasmid (green) and drug loaded particles (red) in culture with no incidence of toxicity.Nano formulated anti-inflammatories in combination with standalone gene product therapy may offer a clinical solution to maximize cardiac gene therapy product effects while minimizing the risk of the host response in the inflammatory myocardial environment." @default.
• W2129155102 created "2016-06-24" @default.
• W2129155102 creator A5002220315 @default.
• W2129155102 creator A5003776673 @default.
• W2129155102 creator A5020890006 @default.
• W2129155102 creator A5023265367 @default.
• W2129155102 creator A5030546093 @default.
• W2129155102 creator A5033556679 @default.
• W2129155102 creator A5070950955 @default.
• W2129155102 creator A5087048448 @default.
• W2129155102 date "2014-01-01" @default.
• W2129155102 modified "2023-09-26" @default.
• W2129155102 title "Anti-inflammatory loaded poly-lactic glycolic acid nanoparticle formulations to enhance myocardial gene transfer: an in-vitro assessment of a drug/gene combination therapeutic approach for direct injection" @default.
• W2129155102 cites W1967089317 @default.
• W2129155102 cites W1974877896 @default.
• W2129155102 cites W1975365820 @default.
• W2129155102 cites W1978368006 @default.
• W2129155102 cites W1980654682 @default.
• W2129155102 cites W1997780004 @default.
• W2129155102 cites W2000772217 @default.
• W2129155102 cites W2004707499 @default.
• W2129155102 cites W2006076378 @default.
• W2129155102 cites W2007261697 @default.
• W2129155102 cites W2014414897 @default.
• W2129155102 cites W2023133801 @default.
• W2129155102 cites W2025091997 @default.
• W2129155102 cites W2041938757 @default.
• W2129155102 cites W2063469067 @default.
• W2129155102 cites W2073545118 @default.
• W2129155102 cites W2075595517 @default.
• W2129155102 cites W2082001997 @default.
• W2129155102 cites W2087863216 @default.
• W2129155102 cites W2094763276 @default.
• W2129155102 cites W2106527251 @default.
• W2129155102 cites W2108297050 @default.
• W2129155102 cites W2112802967 @default.
• W2129155102 cites W2114453747 @default.
• W2129155102 cites W2128688403 @default.
• W2129155102 cites W2150872929 @default.
• W2129155102 cites W2156920534 @default.
• W2129155102 cites W2334079159 @default.
• W2129155102 cites W76918407 @default.
• W2129155102 doi "https://doi.org/10.1186/1479-5876-12-171" @default.
• W2129155102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4068839" @default.
• W2129155102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24934216" @default.
• W2129155102 hasPublicationYear "2014" @default.
• W2129155102 type Work @default.
• W2129155102 sameAs 2129155102 @default.
• W2129155102 citedByCount "16" @default.
• W2129155102 countsByYear W21291551022015 @default.
• W2129155102 countsByYear W21291551022016 @default.
• W2129155102 countsByYear W21291551022017 @default.
• W2129155102 countsByYear W21291551022020 @default.
• W2129155102 countsByYear W21291551022021 @default.
• W2129155102 crossrefType "journal-article" @default.
• W2129155102 hasAuthorship W2129155102A5002220315 @default.
• W2129155102 hasAuthorship W2129155102A5003776673 @default.
• W2129155102 hasAuthorship W2129155102A5020890006 @default.
• W2129155102 hasAuthorship W2129155102A5023265367 @default.
• W2129155102 hasAuthorship W2129155102A5030546093 @default.
• W2129155102 hasAuthorship W2129155102A5033556679 @default.
• W2129155102 hasAuthorship W2129155102A5070950955 @default.
• W2129155102 hasAuthorship W2129155102A5087048448 @default.
• W2129155102 hasBestOaLocation W21291551021 @default.
• W2129155102 hasConcept C136229726 @default.
• W2129155102 hasConcept C141071460 @default.
• W2129155102 hasConcept C155672457 @default.
• W2129155102 hasConcept C171250308 @default.
• W2129155102 hasConcept C185592680 @default.
• W2129155102 hasConcept C192562407 @default.
• W2129155102 hasConcept C202751555 @default.
• W2129155102 hasConcept C2776715498 @default.
• W2129155102 hasConcept C2777628954 @default.
• W2129155102 hasConcept C2780035454 @default.
• W2129155102 hasConcept C2780165375 @default.
• W2129155102 hasConcept C55493867 @default.
• W2129155102 hasConcept C71924100 @default.
• W2129155102 hasConcept C86181022 @default.
• W2129155102 hasConcept C98274493 @default.
• W2129155102 hasConceptScore W2129155102C136229726 @default.
• W2129155102 hasConceptScore W2129155102C141071460 @default.
• W2129155102 hasConceptScore W2129155102C155672457 @default.
• W2129155102 hasConceptScore W2129155102C171250308 @default.
• W2129155102 hasConceptScore W2129155102C185592680 @default.
• W2129155102 hasConceptScore W2129155102C192562407 @default.
• W2129155102 hasConceptScore W2129155102C202751555 @default.
• W2129155102 hasConceptScore W2129155102C2776715498 @default.
• W2129155102 hasConceptScore W2129155102C2777628954 @default.
• W2129155102 hasConceptScore W2129155102C2780035454 @default.
• W2129155102 hasConceptScore W2129155102C2780165375 @default.
• W2129155102 hasConceptScore W2129155102C55493867 @default.
• W2129155102 hasConceptScore W2129155102C71924100 @default.
• W2129155102 hasConceptScore W2129155102C86181022 @default.
• W2129155102 hasConceptScore W2129155102C98274493 @default.
• W2129155102 hasIssue "1" @default.
• W2129155102 hasLocation W21291551021 @default.
• W2129155102 hasLocation W21291551022 @default.
• W2129155102 hasLocation W21291551023 @default.

• next